Literature DB >> 12394957

Effects of calpain inhibitor I on multiple organ failure induced by zymosan in the rat.

Salvatore Cuzzocrea1, Prabal K Chatterjee, Emanuela Mazzon, Ivana Serraino, Laura Dugo, Tommaso Centorrino, Alberto Barbera, Antonio Ciccolo, Francesco Fulia, Michelle C McDonald, Achille P Caputi, Christoph Thiemermann.   

Abstract

OBJECTIVE: Zymosan enhances the formation of reactive oxygen species, which contributes to the pathophysiology of multiple organ failure. We investigated the effects of calpain inhibitor I (5, 10, or 20 mg/kg) on the multiple organ failure caused by zymosan (500 mg/kg, administered intraperitoneally as a suspension in saline) in rats.
SETTING: University research laboratory.
SUBJECTS: Male Sprague-Dawley rats.INTERVENTIONS Multiple organ failure in rats was assessed 18 hrs after administration of zymosan and/or calpain inhibitor I and was monitored for 12 days (for loss of body weight and mortality rate). MEASUREMENT AND MAIN
RESULTS: Treatment of rats with calpain inhibitor I (5, 10, or 20 mg/kg intraperitoneally, 1 and 6 hrs after zymosan) attenuated the peritoneal exudation and the migration of polymorphonuclear cells caused by zymosan in a dose-dependent fashion. Calpain inhibitor I also attenuated the lung, liver, and intestinal injury (histology) as well as the increase in myeloperoxidase activity and malondialdehyde concentrations caused by zymosan in the lung, liver, and intestine. Immunohistochemical analysis for nitrotyrosine and for poly(adenosine-disphosphate-ribose) revealed positive staining in lung, liver, and intestine from zymosan-treated rats. The degree of staining for nitrotyrosine and poly(adenosine-disphosphate-ribose) was reduced markedly in tissue sections obtained from zymosan-treated rats administered calpain inhibitor I (20 mg/kg intraperitoneally). Furthermore, treatment of rats with calpain inhibitor I significantly reduced the expression of inducible nitric oxide synthase and cyclooxygenase-2 in lung, liver, and intestine.
CONCLUSION: This study provides the first evidence that calpain inhibitor I attenuates the degree of zymosan-induced multiple organ failure in the rat.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12394957     DOI: 10.1097/00003246-200210000-00017

Source DB:  PubMed          Journal:  Crit Care Med        ISSN: 0090-3493            Impact factor:   7.598


  6 in total

1.  Activation of calpains mediates early lung neutrophilic inflammation in ventilator-induced lung injury.

Authors:  Dejie Liu; Zhibo Yan; Richard D Minshall; David E Schwartz; Yuguo Chen; Guochang Hu
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2011-12-02       Impact factor: 5.464

2.  Hyperbaric oxygen therapy reduces the toll-like receptor signaling pathway in multiple organ failures.

Authors:  Barbara Rinaldi; Salvatore Cuzzocrea; Maria Donniacuo; Annalisa Capuano; Donatella Di Palma; Francesco Imperatore; Emanuela Mazzon; Rosanna Di Paola; Loredana Sodano; Francesco Rossi
Journal:  Intensive Care Med       Date:  2011-05-13       Impact factor: 17.440

3.  Reactive bone marrow stromal cells attenuate systemic inflammation via sTNFR1.

Authors:  Hiroshi Yagi; Alejandro Soto-Gutierrez; Nalu Navarro-Alvarez; Yaakov Nahmias; Yoni Goldwasser; Yuko Kitagawa; Arno W Tilles; Ronald G Tompkins; Biju Parekkadan; Martin L Yarmush
Journal:  Mol Ther       Date:  2010-07-27       Impact factor: 11.454

4.  Protection by mTOR Inhibition on Zymosan-Induced Systemic Inflammatory Response and Oxidative/Nitrosative Stress: Contribution of mTOR/MEK1/ERK1/2/IKKβ/IκB-α/NF-κB Signalling Pathway.

Authors:  Seyhan Sahan-Firat; Meryem Temiz-Resitoglu; Demet Sinem Guden; Sefika Pinar Kucukkavruk; Bahar Tunctan; Ayse Nihal Sari; Zumrut Kocak; Kafait U Malik
Journal:  Inflammation       Date:  2018-02       Impact factor: 4.092

Review 5.  Development of antiviral therapy for severe acute respiratory syndrome.

Authors:  Jindrich Cinatl; Martin Michaelis; Gerold Hoever; Wolfgang Preiser; Hans Wilhelm Doerr
Journal:  Antiviral Res       Date:  2005-04-26       Impact factor: 5.970

6.  Resolution-phase macrophages possess a unique inflammatory phenotype that is controlled by cAMP.

Authors:  Jonas Bystrom; Ian Evans; Justine Newson; Melanie Stables; Iqbal Toor; Nico van Rooijen; Mark Crawford; Paul Colville-Nash; Stuart Farrow; Derek W Gilroy
Journal:  Blood       Date:  2008-09-08       Impact factor: 22.113

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.